Hookipa Stock Analysis

HOOK -  USA Stock  

USD 9.45  0.25  2.58%

The big decline in price over the last few months for Hookipa Pharmamay raise some interest from traders. The stock closed today at a share price of 9.45 on very low momentum in trading volume. The company management teams failed to add value to investors and positioning the firm supply of money to exploit market volatility in May. However, diversifying your holdings with Hookipa Pharma or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.04. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Hookipa Pharma partners.
Please check Risk vs Return Analysis.

Search Stock Analysis 

The Hookipa Pharma stock analysis report makes it easy to digest most publicly released information about Hookipa Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Hookipa stock analysis module also helps to analyze the Hookipa Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Hookipa Stock Analysis Notes

About 14.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.8. Some equities with similar Price to Book (P/B) outperform the market in the long run. Hookipa Pharma recorded a loss per share of 1.69. The entity had not issued any dividends in recent years. HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York. Hookipa Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 109 people. To learn more about Hookipa Pharma call the company at 431 890 6360 or check out http://www.hookipapharma.com.

Hookipa Pharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Hookipa Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Hookipa Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Hookipa Pharma generates negative expected return over the last 90 days
Hookipa Pharma has high historical volatility and very poor performance
The company reported the previous year's revenue of 21.19 M. Net Loss for the year was (50.39 M) with loss before overhead, payroll, taxes, and interest of (35.2 M).
Hookipa Pharma currently holds about 127.72 M in cash with (46.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.28.
Hookipa Pharma has a frail financial position based on the latest SEC disclosures
Roughly 66.0% of the company shares are owned by institutional investors
Latest headline from www.equities.com: Hookipa Pharma Inc gains 1.2530 percent for June 17 - Equities.com

Hookipa Pharma Upcoming and Recent Events

Earnings reports are used by Hookipa Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Hookipa Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report12th of August 2021
Next Earnings Report11th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End17th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Hookipa Largest EPS Surprises

Earnings surprises can significantly impact Hookipa Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Hookipa Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Hookipa Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Hookipa Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Hookipa Pharma specific information freely available to individual and institutional investors to make a timely investment decision.
7th of June 2021
Submission of Matters to a Vote of Security Holders
12th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
22nd of April 2021
Unclassified Corporate Event
19th of April 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
31st of March 2021
Unclassified Corporate Event
18th of March 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
16th of February 2021
Unclassified Corporate Event
12th of February 2021
Unclassified Corporate Event

Hookipa Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Hookipa Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Hookipa Pharma backward and forwards among themselves. Hookipa Pharma's institutional investor refers to the entity that pools money to purchase Hookipa Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares2.6 M34.3 M
Redmile Group LlcCommon Shares1.8 M24.8 M
Nantahala Capital Management LlcCommon Shares900 K12.1 M
Vanguard Group IncCommon Shares888.7 K12 M
Blackrock IncCommon Shares743.8 K10 M
Hillhouse Capital Advisors LtdCommon Shares735.6 K9.9 M
Baker Bros Advisors LpCommon Shares700.5 K9.4 M
Citadel Advisors LlcPut Options106.7 K1.4 M
Note, although Hookipa Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Hookipa Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 281.75 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hookipa Pharma's market, we take the total number of its shares issued and multiply it by Hookipa Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Hookipa Profitablity

Hookipa Pharma's profitability indicators refer to fundamental financial ratios that showcase Hookipa Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Hookipa Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Hookipa Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Hookipa Pharma's profitability requires more research than a typical breakdown of Hookipa Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (237.83) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (283.16) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -2.83.
Last ReportedProjected for 2021
Return on Average Assets(0.30) (0.33) 
Return on Average Equity(0.38) (0.39) 
Return on Invested Capital(1.40) (1.51) 
Return on Sales(2.21) (2.38) 

Management Efficiency

The entity has return on total asset (ROA) of (24.52) % which means that it has lost $24.52 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (40.47) %, meaning that it created substantial loss on money invested by shareholders. Hookipa Pharma management efficiency ratios could be used to measure how well hookipa pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Average Assets is estimated to decrease to -0.33. The current Return on Average Equity is estimated to decrease to -0.39. The current Liabilities Non Current is estimated to increase to about 11.1 M, while Total Liabilities is projected to decrease to under 30.1 M.
Last ReportedProjected for 2021
Book Value per Share 6.08  6.56 
Enterprise Value over EBIT(4.50) (4.86) 
Enterprise Value over EBITDA(5.44) (5.88) 
Price to Book Value 1.82  1.90 
Tangible Assets Book Value per Share 7.32  7.51 
Enterprise Value213.1 M231 M
Tangible Asset Value187.8 M167.4 M

Technical Drivers

As of the 19th of June, Hookipa Pharma retains the market risk adjusted performance of 1.06, and Risk Adjusted Performance of (0.024951). Hookipa Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for Hookipa Pharma, which can be compared to its competitors. Please check out Hookipa Pharma standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Hookipa Pharma is priced fairly, providing market reflects its last-minute price of 9.45 per share. Given that Hookipa Pharma has jensen alpha of (0.28), we strongly advise you to confirm Hookipa Pharma's regular market performance to make sure the company can sustain itself at a future point.

Hookipa Pharma Price Movement Analysis

The output start index for this execution was six with a total number of output elements of fifty-five. The Weighted Moving Average calculates a weight for each value in Hookipa Pharma price series with the more recent values given greater weights. View also all equity analysis or get more info about weighted moving average overlap studies indicator.

Hookipa Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Hookipa Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Hookipa Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Hookipa Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Soria Jeancharles over two weeks ago via Macroaxis 
Acquisition by Soria Jeancharles of 9600 shares of Hookipa Pharma subject to Rule 16b-3
Sofinnova Capital Vi Fcpr over a month ago via Macroaxis 
Sale by Sofinnova Capital Vi Fcpr of 328620 shares of Hookipa Pharma
Baker Christine D over a month ago via Macroaxis 
Acquisition by Baker Christine D of 49950 shares of Hookipa Pharma subject to Rule 16b-3
Sofinnova Capital Vi Fcpr over two months ago via Macroaxis 
Sale by Sofinnova Capital Vi Fcpr of 36829 shares of Hookipa Pharma
Sofinnova Capital Vi Fcpr over two months ago via Macroaxis 
Sale by Sofinnova Capital Vi Fcpr of 28546 shares of Hookipa Pharma
Sofinnova Capital Vi Fcpr over two months ago via Macroaxis 
Sale by Sofinnova Capital Vi Fcpr of 52690 shares of Hookipa Pharma
Sofinnova Capital Vi Fcpr over two months ago via Macroaxis 
Sale by Sofinnova Capital Vi Fcpr of 40000 shares of Hookipa Pharma
Sofinnova Capital Vi Fcpr over two months ago via Macroaxis 
Sale by Sofinnova Capital Vi Fcpr of 40534 shares of Hookipa Pharma
Sofinnova Capital Vi Fcpr over two months ago via Macroaxis 
Sale by Sofinnova Capital Vi Fcpr of 166230 shares of Hookipa Pharma
Baker Christine D over two months ago via Macroaxis 
Hookipa Pharma exotic insider transaction detected
Matushansky Igor over six months ago via Macroaxis 
Exercise or conversion by Matushansky Igor of 5965 shares of HOOKIPA PHARMA subject to Rule 16b-3
Soria Jeancharles over six months ago via Macroaxis 
Acquisition by Soria Jeancharles of 19200 shares of HOOKIPA PHARMA subject to Rule 16b-3

Hookipa Pharma Technical and Predictive Indicators

Hookipa Pharma Forecast Models

Hookipa Pharma time-series forecasting models is one of many Hookipa Pharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Hookipa Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Hookipa Pharma Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Hookipa Pharma stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Hookipa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Hookipa Pharma. By using and applying Hookipa Stock analysis, traders can create a robust methodology for identifying Hookipa entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(2.00) (2.16) 
Gross Margin 0.90  0.89 
Profit Margin(2.25) (2.43) 
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York. Hookipa Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 109 people.

Current Hookipa Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Hookipa analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Hookipa analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Hookipa Pharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Hookipa analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Hookipa stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Hookipa Pharma, talking to its executives and customers, or listening to Hookipa conference calls.
Hookipa Analyst Advice Details

Hookipa Stock Analysis Indicators

Hookipa Pharma stock analysis indicators help investors evaluate how Hookipa Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Hookipa Pharma shares will generate the highest return on investment. By understating and applying Hookipa Pharma stock analysis, traders can identify Hookipa Pharma position entry and exit signals to maximize returns.
Quick Ratio7.24
Fifty Two Week Low8.10
Revenue Growth43.40%
Shares Short Prior Month1.36M
Average Daily Volume Last 10 Day1.41M
Average Daily Volume In Three Month385.94k
Shares Percent Shares Out4.63%
Gross Margins-199.33%
Short Percent Of Float6.16%
Forward Price Earnings-3.62
Float Shares14.99M
Fifty Two Week High20.00
Enterprise Value To Ebitda-6.83
Fifty Day Average14.83
Two Hundred Day Average12.81
Enterprise Value To Revenue17.94
Please check Risk vs Return Analysis. Note that the Hookipa Pharma information on this page should be used as a complementary analysis to other Hookipa Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Hookipa Pharma Stock analysis

When running Hookipa Pharma price analysis, check to measure Hookipa Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hookipa Pharma is operating at the current time. Most of Hookipa Pharma's value examination focuses on studying past and present price action to predict the probability of Hookipa Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Hookipa Pharma's price. Additionally, you may evaluate how the addition of Hookipa Pharma to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Fundamental Analysis
View fundamental data based on most recent published financial statements
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Hookipa Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.